PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-197.85
Negative P/E while Drug Manufacturers - Specialty & Generic median is -1.25. Seth Klarman would scrutinize path to profitability versus peers.
52.23
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.28. Jim Chanos would check for potential multiple compression risks.
3.63
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.58. Jim Chanos would check for potential asset write-down risks.
-93.00
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -0.07. Seth Klarman would investigate cash flow improvement potential.
-154.76
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
3.63
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.58. Jim Chanos would check for valuation bubble risks.
-0.13%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -0.07%. Seth Klarman would investigate path to profitability.
-1.08%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.01%. Seth Klarman would investigate cash flow improvement potential.